Sermorelin
200–300 mcg · Daily, PM
Evidence
- Human Studies
- 20
- Animal Studies
- 15
- Clinical Status
- Off-label
- Confidence
- Moderate
- Long-Term Safety
- Established for the discontinued FDA-approved diagnostic product; long-term safety data for ongoing off-label anti-aging use is much thinner
What this score is: a measure of how much research exists and how far along it is (animal-only vs. human trials, research-stage vs. FDA approved) — not how safe, effective, or worth trying a compound is. A low score usually means “early stage” or “understudied,” not “bad.” A high score doesn’t mean “better” for your goals than a lower-scored one.
This is not my personal rating of the compound, not a recommendation, and not medical advice. It’s a general research synthesis for informational purposes only, not a live literature count. See the linked research and talk to a licensed clinician before making decisions based on it.
Mechanism
Sermorelin is a synthetic analogue of the first 29 amino acids of growth hormone-releasing hormone (GHRH), stimulating the pituitary to release its own GH in a pulsatile pattern. It was FDA-approved (as Geref) for diagnosing GH deficiency in children before being discontinued commercially; it is now available primarily through compounding pharmacies.
Common Protocols
- 200–300 mcg subcutaneous nightly, ideally on an empty stomach before bed to align with natural GH pulses
- Often used in cycles of several months with periodic breaks
Side Effects
- Injection site redness or itching
- Flushing or headache shortly after injection
- Rare: dizziness
Interactions
- Effects may be blunted by high blood sugar around the time of injection — avoid a large meal immediately before dosing
Practical Details
- Cost
- $$
- Typical Vial Size
- 5 mg
- Storage
- Refrigerate after reconstitution
Research Links
GHRH analogue; short half-life, inject before bed